Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has reported preliminary Q2 total revenue exceeding $47 million, representing over 23% growth compared to last year. This surpasses the estimated $44.894 million.
July 08, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris Biopharma's preliminary Q2 revenue exceeds $47 million, showing over 23% growth year-over-year and surpassing the estimated $44.894 million.
The significant revenue growth and surpassing of estimates are positive indicators for Xeris Biopharma, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100